According to these findings, baseline serum NGAL might serve as a predictor of the development of CI-AKI and cardiac and cerebrovascular outcomes in patients with CAD undergoing PCI before the administration of contrast medium. The gene discussed is LCN2; the disease is coronary artery disorder.